All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
5 warning events since 2017; the latest 2026-08-10.
From the record
Lexaria Bioscience Corp.'s filings since 2017 show 5 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-08-10); an auditor change (8-K item 4.01, the latest 2022-11-28) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+17.5% a year over 6 filed years; profitable in 0 of 6.
From the record
Lexaria Bioscience Corp.'s 6 filed years say what it did: revenue went from $315 thousand in fiscal 2020 to $706 thousand in fiscal 2025, up 17.5% a year; it rose in 3 of 5 years; the deepest fall was 69% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Lexaria Bioscience Corp.'s shareholder treatment is put at 8.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 20% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -398%: lost 398¢ per shareholder dollar. Leverage 28%: owes 28¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-08-31, Lexaria Bioscience Corp. lost about 398 cents for every dollar of shareholders' money, and gross profitability: its products earned about 17 cents per dollar of everything the company owns. Leverage: it owed about 28 cents per dollar of assets, and net share issuance: its share count grew 45.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 39% of 315 in its family; net margin -1686%.
From the record
Lexaria Bioscience Corp.'s standing among 315 graded names in its industry family: revenue of $706 thousand in fiscal 2025 ranks in the bottom 19% by size; a net margin of -1686% ranks in the bottom 26%; revenue growth of 40.3% a year over the last 3 filed years ranks in the top 26% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Lexaria Bioscience Corp.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 34% of 273 in its family for room to expand.
From the record
Lexaria Bioscience Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against no long-term debt tagged leaves 43.2% of its assets as net cash, top 36% of its family; cash from operations less capital spending is -1483.9% of revenue (bottom 20%); a gross margin of 99.6% (top 2%); research spending of 1167.1% of revenue (top 19%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 25% of 306 in its family for growth drivers.
From the record
Lexaria Bioscience Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 40.3% a year over the last three filed years against 17.5% over all 6, speeding up (top 12% of its family); the newest year grew 52.1% (top 25%); research spending grew 64.7% a year (top 5%); capital spending grew -20.6% a year (bottom 43%) (its annual reports). Lexaria Bioscience Corp. reported 2 product lines in fiscal 2025: IP Licensing at $696 thousand (99%), B Two B at $10 thousand (1%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 44% of 233 in its family for expectations against reality.
From the record
Lexaria Bioscience Corp.'s newest year against its own record: revenue of $706 thousand in fiscal 2025 came in 12.8% above the $626 thousand its prior three years' pace pointed to (top 32% of its family); net income of $12 million against a prior three-year average of $7 million (bottom 18%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 17%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made